© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
Attenuation of experimental autoimmune myocarditis by blocking activated T cells through inducible costimulatory molecule pathway
aDepartment of Cardiovascular Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan
bThe First Department of Internal Medicine, Shinshu University School of Medicine, Nagano, Japan
cPharmaceutical Frontier Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., Kanagawa, Japan
dDivision of Molecular Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
isobemi.cvm{at}tmd.ac.jp
* Corresponding author. Tel.: +81-03-5803-5951; fax: +81-03-5803-0238.
Objective: Inducible costimulator (ICOS) is a member of the CD28 family. Although inflammation is an essential pathological feature of myocarditis, the role of ICOS in myocarditis remains unclear. Methods and Results: Lewis rats were immunized on day 0 with purified porcine cardiac myosin to establish experimental autoimmune myocarditis (EAM). Flow cytometry was used to examine expression of ICOS on myocardial infiltrating cells. Anti-ICOS antibody or ICOS-immunoglobulin (ICOSIg) was administered intravenously, and rats were killed on day 14 or 21 to study effects of ICOS/ICOS-ligand (ICOSL) pathway blockade during the antigen priming phase (days 0–14) or immune response phase (days 14–21), respectively. The heart weight to body weight ratio was determined, and histological examination and echocardiogram were performed to evaluate the severity of the disease. Cytokine expression in the heart and T cell proliferation against cardiac myosin were analyzed. Flow cytometry revealed that the majority of infiltrating cells, especially CD4-positive cells, expressed ICOS. Blockade of the ICOS/ICOSL pathway during the immune response phase attenuated EAM development. However, blockade of the ICOS/ICOSL pathway during the antigen priming phase did not attenuate and exacerbate EAM. Blockade of T cell activation through ICOS suppressed expression of cytokines including INF-
, IL-4, IL-6, IL-10, IL-1β, and TNF-
and inhibited T cell proliferation in vitro. Conclusions: Blockade of T cell activation through ICOS during the immune response phase regulates development of EAM, and therefore, ICOS may be an effective target for treating myocarditis.
KEYWORDS Heart failure; Immunology; Leukocytes; Lymphatic circulation; Myocarditis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Hishikari, J.-i. Suzuki, M. Ogawa, K. Isobe, T. Takahashi, M. Onishi, K. Takayama, and M. Isobe Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury Cardiovasc Res, January 1, 2009; 81(1): 123 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Katsumata, M. Harigai, T. Sugiura, M. Kawamoto, Y. Kawaguchi, Y. Matsumoto, K. Kohyama, M. Soejima, N. Kamatani, and M. Hara Attenuation of Experimental Autoimmune Myositis by Blocking ICOS-ICOS Ligand Interaction J. Immunol., September 15, 2007; 179(6): 3772 - 3779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Seko, H. Yagita, K. Okumura, M. Azuma, and R. Nagai Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3 Cardiovasc Res, July 1, 2007; 75(1): 158 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-i. Suzuki, M. Ogawa, H. Futamatsu, H. Kosuge, Y. M. Sagesaka, and M. Isobe Tea catechins improve left ventricular dysfunction, suppress myocardial inflammation and fibrosis, and alter cytokine expression in rat autoimmune myocarditis Eur J Heart Fail, February 1, 2007; 9(2): 152 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nishii, T. Inomata, H. Niwano, H. Takehana, I. Takeuchi, H. Nakano, H. Shinagawa, T. Naruke, T. Koitabashi, J.-i. Nakahata, et al. {beta}2-Adrenergic Agonists Suppress Rat Autoimmune Myocarditis: Potential Role of {beta}2-Adrenergic Stimulants as New Therapeutic Agents for Myocarditis Circulation, August 29, 2006; 114(9): 936 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Odobasic, A. R. Kitching, T. J. Semple, and S. R. Holdsworth Inducible Co-Stimulatory Molecule Ligand Is Protective during the Induction and Effector Phases of Crescentic Glomerulonephritis J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1044 - 1053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-i. Suzuki, M. Ogawa, Y. M. Sagesaka, and M. Isobe Tea catechins attenuate ventricular remodeling and graft arterial diseases in murine cardiac allografts Cardiovasc Res, January 1, 2006; 69(1): 272 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Futamatsu, J.-i. Suzuki, S. Mizuno, N. Koga, S. Adachi, H. Kosuge, Y. Maejima, K. Hirao, T. Nakamura, and M. Isobe Hepatocyte Growth Factor Ameliorates the Progression of Experimental Autoimmune Myocarditis: A Potential Role for Induction of T Helper 2 Cytokines Circ. Res., April 29, 2005; 96(8): 823 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Azuma, J.-i. Suzuki, M. Ogawa, H. Futamatsu, N. Koga, Y. Onai, H. Kosuge, and M. Isobe HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation Cardiovasc Res, December 1, 2004; 64(3): 412 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Liu, H. Nakamura, K. Shioji, M. Tanito, S.-i. Oka, M. K. Ahsan, A. Son, Y. Ishii, C. Kishimoto, and J. Yodoi Thioredoxin-1 Ameliorates Myosin-Induced Autoimmune Myocarditis by Suppressing Chemokine Expressions and Leukocyte Chemotaxis in Mice Circulation, September 7, 2004; 110(10): 1276 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kosuge, J.-i. Suzuki, T. Kakuta, G. Haraguchi, N. Koga, H. Futamatsu, R. Gotoh, M. Inobe, M. Isobe, and T. Uede Attenuation of Graft Arterial Disease by Manipulation of the LIGHT Pathway Arterioscler Thromb Vasc Biol, August 1, 2004; 24(8): 1409 - 1415. [Abstract] [Full Text] [PDF]
|
|